Thermo Fisher Scientific (TMO) Stock Price, News & Analysis

Company Overview

Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, reagents and consumables, software, and services that advance research, diagnostics, and pharmaceutical manufacturing. The company’s main business activities are organized into four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its product offerings include benchtop and high-throughput instruments, chromatography and mass spectrometry systems, cell culture media, antibodies and assays, clinical diagnostic kits, and custom biopharma development and manufacturing services.

Formed in 2006 through the merger of Thermo Electron and Fisher Scientific, Thermo Fisher has built a global reputation by combining deep domain expertise with broad product portfolios. Over the years, it has expanded both organically and through targeted acquisitions to address emerging challenges in genomics, proteomics, clinical diagnostics, personalized medicine, and environmental testing. The company continues to invest in research and development, aiming to deliver novel solutions that accelerate scientific discovery and improve patient outcomes.

Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific operates in more than 50 countries and serves customers across North America, Europe, Asia Pacific, Latin America, and the Middle East. Its geographic reach supports a diverse clientele, including academic institutions, government agencies, hospitals, pharmaceutical and biotechnology companies, and industrial laboratories. The company’s logistics network and field service teams are designed to ensure reliable product delivery, technical support, and application training on a global scale.

Under the leadership of President and Chief Executive Officer Marc N. Casper, Thermo Fisher Scientific maintains a focus on innovation, operational excellence, and sustainable growth. The company emphasizes collaboration with its customers and partners to co-develop solutions that address complex scientific and healthcare challenges. By aligning strategic investments with evolving market needs, Thermo Fisher seeks to reinforce its position as a trusted partner in the global life sciences and diagnostics ecosystem.

Key Stats

• Today's Range: $479.46 to $491.26
• 50-Day Range: $405.15 to $500.24
• 52-Week Range: $385.46 to $623.77
• Volume: 1.54 million shs
• Average Volume: 1.51 million shs
• Market Capitalization: $181.55 billion
• P/E Ratio: 27.89
• Dividend Yield: 0.36%
• Price Target: $592.24
• Consensus Rating: Moderate Buy

Thermo Fisher Scientific Stock Analysis - MarketRank™

Thermo Fisher Scientific scored higher than 99% of companies evaluated by MarketBeat, and ranked 11th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Thermo Fisher Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 17 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Thermo Fisher Scientific has a consensus price target of $592.24, representing about 23.5% upside from its current price of $479.48.

Amount of Analyst Coverage

Thermo Fisher Scientific has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.79%

Earnings Growth

Earnings for Thermo Fisher Scientific are expected to grow by 9.79% in the coming year, from $23.28 to $25.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Thermo Fisher Scientific is 27.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Thermo Fisher Scientific is 27.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.63.

Price to Earnings Growth Ratio

Thermo Fisher Scientific has a PEG Ratio of 2.56. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Thermo Fisher Scientific has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.05% of the float of Thermo Fisher Scientific has been sold short.

Short Interest Ratio / Days to Cover

Thermo Fisher Scientific has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Thermo Fisher Scientific has recently increased by 3.14%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Thermo Fisher Scientific has a dividend yield of 0.35%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Thermo Fisher Scientific has been increasing its dividend for 8 years.

Dividend Coverage

The dividend payout ratio of Thermo Fisher Scientific is 9.95%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Thermo Fisher Scientific will have a dividend payout ratio of 6.73% next year. This indicates that Thermo Fisher Scientific will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -1.44

Percentage of Shares Shorted

1.05% of the float of Thermo Fisher Scientific has been sold short.

Short Interest Ratio / Days to Cover

Thermo Fisher Scientific has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Thermo Fisher Scientific has recently increased by 3.14%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.30

News Sentiment

Thermo Fisher Scientific has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 75 news articles for Thermo Fisher Scientific this week, compared to 45 articles on an average week.

Search Interest

Only 37 people have searched for TMO on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.

MarketBeat Follows

17 people have added Thermo Fisher Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 42% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Thermo Fisher Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,182,963.00 in company stock.

Percentage Held by Insiders

Only 0.33% of the stock of Thermo Fisher Scientific is held by insiders.

Percentage Held by Institutions

89.23% of the stock of Thermo Fisher Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TMO Stock Analysis - Frequently Asked Questions

How have TMO shares performed this year?

Thermo Fisher Scientific's stock was trading at $520.23 at the start of the year. Since then, TMO shares have decreased by 7.8% and is now trading at $479.48.

How were Thermo Fisher Scientific's earnings last quarter?

Thermo Fisher Scientific Inc. (NYSE:TMO) posted its quarterly earnings results on Wednesday, July, 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm's revenue for the quarter was up 2.9% on a year-over-year basis.
Read the conference call transcript.

Is Thermo Fisher Scientific doing a stock buyback?

Thermo Fisher Scientific's board initiated a stock repurchase plan on Friday, November 15th 2024, which authorizes the company to buy back $4,000,000,000 in shares, according to EventVestor. This means that the company could buy up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.

Does Thermo Fisher Scientific have any subsidiaries?

Thermo Fisher Scientific subsidiaries include Henogen, Phinotex, Qiagen, Brammer Bio, HighChem, Gatan Inc, IntegenX, and more.

Who are Thermo Fisher Scientific's major shareholders?

Top institutional investors of Thermo Fisher Scientific include Vanguard Group Inc. (8.95%), State Street Corp (4.36%), Geode Capital Management LLC (2.15%) and Norges Bank (1.48%). Insiders that own company stock include Marc N Casper, Stephen Williamson, Gianluca Pettiti, Jim P Manzi, Lisa P Britt, Michael A Boxer, Joseph R Holmes and Debora L Spar.
View institutional ownership trends.

How do I buy shares of Thermo Fisher Scientific?

Shares of TMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Thermo Fisher Scientific own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Thermo Fisher Scientific investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), The Goldman Sachs Group (GS), Illinois Tool Works (ITW) and NVIDIA (NVDA).

Company Calendar

• Record date for 7/15 Dividend: 6/13/2025
• Ex-Dividend for 7/15 Dividend: 6/13/2025
• Dividend Payable: 7/15/2025
• Last Earnings: 7/23/2025
• Today: 9/14/2025
• Record date for 10/15 Dividend: 9/15/2025
• Ex-Dividend for 10/15 Dividend: 9/15/2025
• Dividend Payable: 10/15/2025
• Next Earnings (Estimated): 10/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:TMO
• CIK: 97745
• Web: www.thermofisher.com
• Phone: (781) 622-1000
• Fax: 781-622-1207
• Employees: 125,000
• Year Founded: 1960

Price Target and Rating

• Average Price Target for Thermo Fisher Scientific: $592.24
• High Price Target: $686.00
• Low Price Target: $470.00
• Potential Upside/Downside: +23.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $17.29
• Trailing P/E Ratio: 27.73
• Forward P/E Ratio: 20.60
• P/E Growth: 2.56
• Net Income: $6.34 billion
• Net Margins: 15.24%
• Pretax Margin: 16.23%
• Return on Equity: 16.82%
• Return on Assets: 8.38%

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 1.93
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $43.21 billion
• Price / Sales: 4.19
• Cash Flow: $30.04 per share
• Price / Cash Flow: 15.96
• Book Value: $129.54 per share
• Price / Book: 3.70

Miscellaneous

• Outstanding Shares: 377,612,000
• Free Float: 376,366,000
• Market Cap: $181.06 billion
• Optionable: Optionable
• Beta: 0.75